Aug 2026· Chimia (Basel)· Vol 80 7-8, pp.
501-508
· 0 citations· 4 references
Medicine
TL;DR
Together, these examples define an expanding pharmacological vocabulary for kinase drug discovery: one that asks not only whether a molecule inhibits its target kinase, but how ligand binding rewires protein stability, interactions, localisation, and function.
Abstract
Kinase inhibitors are a cornerstone of modern drug discovery, with more than 100 approved compounds which have had a transformative impact in precision oncology and inflammatory disease. Their success has rested largely on small-molecule control of catalytic activity through ATP-site engagement; a framework that leaves important biology unaddressed, including non-catalytic kinase functions, resistance driven by active-site mutation, and the limits of selectivity imposed by pocket conservation. Against this backdrop, the observation that kinase inhibitors can reduce target protein abundance has gained new mechanistic depth. Chaperone deprivation, supercharging of native degradation circuits, and context-dependent mutant-selective depletion mark distinct routes through which inhibitor binding can intersect with cellular proteostasis. The kinase inhibitor CR8 extends this logic into chemically encoded degradation: CR8 acts as a molecular glue degrader by creating, within the ligand-bound kinase complex, a composite surface that directly recruits a ubiquitin ligase, resulting in cyclin K degradation. Thalidomide analogues can degrade kinases through scaffolds that do not bind the kinase in isolation: ligase-binding compounds that recruit neosubstrate kinases through recognition of structural surface degrons. Deliberately engineered PROTACs encode ligase-target proximity through heterobifunctional architecture to convert kinase binders into degraders. Beyond degradation, induced-proximity mechanisms - from the clinically established rapamycin to bifunctional molecules that redirect kinase activity or restrict inhibition to tumour cells - show how small molecules can reshape kinase interaction states rather than simply block active sites. Together, these examples define an expanding pharmacological vocabulary for kinase drug discovery: one that asks not only whether a molecule inhibits its target kinase, but how ligand binding rewires protein stability, interactions, localisation, and function.
The structural and medicinal chemistry principles underlying (i) allosteric inhibition and (ii) proximity-induced degradation are summarized, with an emphasis on design logic, structure-activity relationships, and key liabilities in the beyond rule of five space.
Mei Zhou, Linshan Li, Xiao-Juan Tang et al.· Future Medicinal Chemistry· 0 citations
Members of the DYRK kinase family have been implicated in the regulation of key metabolic processes. In particular, DYRK1B plays a central role in hepatic lipid metabolism and fatty liver disease. Notably, these functions depend not only on the enzyme’s catalytic activity but also on scaffolding properties. Consequentl...
Miriam S. Ems, Mattias F. Lindberg, Till Adhikary et al.· ACS Pharmacology & Translati...· 0 citations
A summary of the design of irreversible inhibitors, reversible inhibitors, and Proteolysis-targeting chimera (PROTAC) degraders targeting BTK is provided and how the design of these inhibitors and PROTACs leads to a more selective inhibition and degradation of BTK is reviewed.
Eduardo Bravo, C. C. Pastrana, Erica N Lamkin et al.· Cells· 0 citations
This Perspective discusses three complementary strategies for selective CK2 inhibition: targeting the CK2α/β interface with small molecules, disrupting the same interface with conformationally constrained peptides, and exploiting the cryptic αD pocket for dual-site inhibitor design.
A. Sokhal, S. Krajcovicova, J. Iegre et al.· Journal of Medicinal Chemist...· 0 citations
The current ATM, ATR, DNA-PK, CHK1, CHK2 and WEE1 inhibitors that show the most promise as monotherapies and combination treatments in solid tumours are discussed, as well as the potential benefits of using TPD technology over small-molecule inhibitors.
Lauryn Buckley-Benbow, Antonia M. Rout, Andrew B. Fielding et al.· TARGETS· 0 citations
The development of KRAS inhibitors is explored, highlighting the challenges due to KRAS’s ‘undruggable’ nature and the success of covalent inhibitors such as sotorasib for KRASG12C mutant cancers, and the ubiquitin–proteasome system is highlighted as key regulators of KRAS stability and signaling networks, providing co...
Yeonjoo Lee, Sua Hwang, Hyungkyung Shin et al.· Experimental and Molecular M...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.